The decrease in CarnoSyn ® beta-alanine royalty, licensing, and raw material sales revenue during the second quarter of fiscal 2025 was primarily due to a decrease in orders from existing customers.

QUAD’s current management team will continue running the combined company after the Transaction.

None of the three big indexes marked a feat worth hailing on Friday: the S&P 500 closed flat, the Dow Jones Industrial Average finished slightly lower, and the Nasdaq Composite ticked a smidge higher.

The ITC issued a Limited Exclusion Order against all Respondents and Cease and Desist Orders against Respondents Delta Electronics (Americas) Ltd., Quanta Computer USA Inc. and Quanta Computer Inc., ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Key Financial Highlights: Operating Results for the Three Months Ended December 31, 2024: ...

IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...

The fourth-quarter earnings season was another one marked by explosive growth and record profits for the top hyperscalers ...

We recently compiled a list of the 10 Best Momentum Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Case Reports in the Journal of the American College of Cardiology Underscore the Critical Role of Blood Volume Analysis in Optimizing Heart ...

PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is ...

NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- AMC Networks Inc. ("AMC Networks" or the "Company") (NASDAQ: AMCX) today reported financial results for the fourth quarter and full year ended December 31, ...